Literature DB >> 11738104

Decreased expression of an ATP-binding cassette transporter, MRP2, in human livers with hepatitis C virus infection.

E Hinoshita1, K Taguchi, A Inokuchi, T Uchiumi, N Kinukawa, M Shimada, M Tsuneyoshi, K Sugimachi, M Kuwano.   

Abstract

BACKGROUND/AIMS: To understand hepatic injury during the process of hepatitis viral infection, determination of liver-specific functions at molecular levels is critical. Because the transport of endogenous/exogenous toxic substances is an intrinsically important hepatic function, we examined whether expression of the ATP-binding cassette (ABC) transporter gene was affected in patients with hepatitis viral infection.
METHODS: To determine which ABC transporter was expressed differently in patients with hepatic viral infection, we assayed the expression of MDR1, MDR3, MRP1, MRP2, and MRP3 in non-cancerous regions in the liver of 42 patients with hepatic tumors using both quantitative RT-PCR and immunological staining analysis, and compared the hepatic expression levels between patients with hepatitis viral infection and non-infected controls.
RESULTS: Of the five ABC transporter genes studied, the mRNAs of MRP2 and MRP3 were highly expressed in the human liver. There was a significant reduction in MRP2 expression to 29% in the virus-infected liver. Treatment of hepatic cells with inflammatory cytokines resulted in decreased mRNA levels of MRP2 and decreased MRP2 promoter activity.
CONCLUSIONS: The down-regulation of MRP2 might induce a failure in the transport of various genotoxic substances in the liver with hepatitis virus infection.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11738104     DOI: 10.1016/s0168-8278(01)00216-1

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  16 in total

Review 1.  Human pharmacogenomic variations and their implications for antifungal efficacy.

Authors:  Joseph Meletiadis; Stephen Chanock; Thomas J Walsh
Journal:  Clin Microbiol Rev       Date:  2006-10       Impact factor: 26.132

Review 2.  Vertical hepatitis C virus transmission: Main questions and answers.

Authors:  Grazia Tosone; Alberto Enrico Maraolo; Silvia Mascolo; Giulia Palmiero; Orsola Tambaro; Raffaele Orlando
Journal:  World J Hepatol       Date:  2014-08-27

Review 3.  Regulation of hepatic ABCC transporters by xenobiotics and in disease states.

Authors:  Xinsheng Gu; Jose E Manautou
Journal:  Drug Metab Rev       Date:  2010-08       Impact factor: 4.518

Review 4.  Influence of drug transport proteins on the pharmacokinetics and drug interactions of HIV protease inhibitors.

Authors:  Latoya Griffin; Pieter Annaert; Kim L R Brouwer
Journal:  J Pharm Sci       Date:  2011-06-22       Impact factor: 3.534

5.  T1 mapping for liver function evaluation in gadoxetic acid-enhanced MR imaging: comparison of look-locker inversion recovery and B1 inhomogeneity-corrected variable flip angle method.

Authors:  Ji Eun Kim; Hyun Ok Kim; Kyungsoo Bae; Dae Seob Choi; Dominik Nickel
Journal:  Eur Radiol       Date:  2019-03-22       Impact factor: 5.315

6.  Evaluation of hepatocellular carcinoma development in patients with chronic hepatitis C by EOB-MRI.

Authors:  Shunsuke Nojiri; Kei Fujiwara; Noboru Shinkai; Mio Endo; Takashi Joh
Journal:  World J Hepatol       Date:  2014-12-27

7.  Hepatic metabolism and biliary excretion of silymarin flavonolignans in isolated perfused rat livers: role of multidrug resistance-associated protein 2 (Abcc2).

Authors:  Sonia R Miranda; Jin Kyung Lee; Kim L R Brouwer; Zhiming Wen; Philip C Smith; Roy L Hawke
Journal:  Drug Metab Dispos       Date:  2008-08-07       Impact factor: 3.922

Review 8.  Cholestasis.

Authors:  R Oude Elferink
Journal:  Gut       Date:  2003-05       Impact factor: 23.059

Review 9.  Hepatitis C and pregnancy.

Authors:  Annarosa Floreani
Journal:  World J Gastroenterol       Date:  2013-10-28       Impact factor: 5.742

Review 10.  Bile acid transporters and regulatory nuclear receptors in the liver and beyond.

Authors:  Emina Halilbasic; Thierry Claudel; Michael Trauner
Journal:  J Hepatol       Date:  2012-08-08       Impact factor: 25.083

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.